Travere Therapeutics, Inc. TVTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$37.1M— | —— | $25.71M+302% | -$12.76M+69.1% | -$41.23M+31.6% | ||
| $25.21M+39.0% | $18.14M+14.9% | $15.79M+12.6% | $14.02M+9.5% | $12.8M+5.9% | ||
| $16.15M+40.8% | $11.46M+1.8% | $11.26M+5.8% | $10.65M-7.3% | $11.49M+24.7% | ||
| -$40.37M-167% | $60.68M— | —— | —— | -$42.19M-18.1% | ||
| $21.55M— | —— | $86.59M+1,685% | $4.85M-88.3% | $41.29M— | ||
| $4.2M— | —— | -$65.34M-4,530% | $1.48M-60.3% | $3.72M-97.3% | ||
| -$14.67M— | —— | $35.78M+170% | $13.26M+294% | $3.36M-84.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.